Owing to the recent progress in immunology, many monoclonal antibodies against various malignant tissues and their products have been developed and some of them are now in clinical use. One of these is OC125, which is obtained by immunising mice with ovarian cancer cell lines (Bast et al., 1981) . The antigen recognised by this antibody, CA125, has been proved to show increased serum levels in a high percentage of patients with ovarian cancer and endometriosis (Bast et al., 1983; Kabawat et al., 1983a; Baumah et al., 1987; Fleuren et al., 1987; Takahashi et al., 1986) . Recently, other antibodies, designated 130-20 and 145-9 have been prepared by immunising mice with the lung adenocarcinoma cell line PC-9 (Matsuoka et al., 1987; Kunimatsu et al., 1988) . These antibodies recognise the same molecule as does OC125, but the epitopes which are recognised are different for each antibody. As the antibodies 13-20 and 145-9 were raised against a pulmonary adenocarcinoma cell line, it seemed possible that CA125 could also be a tumour marker for lung adenocarcinoma. We examined serum CA 125 levels in patients with lung cancer by one-step immunoradiometric assay, and found, contrary to the first hypothesis, that this antigen was not specific only to lung adenocarcinoma but it also reflected the extent of lung cancers of various types including adenocarcinoma and their prognosis.
Materials and methods

Assay kit
The assay kit for CA125 was kindly donated by the Daiichi Radioisotope Laboratory (Tokyo, Japan). The assay method was a one-step immunoradiometric assay using '25I-labelled antibody 130-20 solution and latex beads coated with antibody 145-9. The correlation between CA125 levels measured by the current method and those measured by the conventional method (ELSA CA125 kit, CIS, Saclay, France) was y = 0.886x + 2.405, r = 0.931, n = 477. 
Subjects
Results
Normal range ofserum CA 125 using the one-step immunoradiometric assay kit CA125 levels ranged from 2.7 to 87.6 U ml' (mean ± s.d. 15.3 ± 9.9). There existed a significant difference between the serum CA125 level of males and females. These were 9.6 + 5.1 U ml-' and 17.3 ± 10.5 U ml-', respectively (P<0.01) (Figure 1 ). Among the females, there existed a significant difference between the serum CA125 levels of younger subjects (younger than 50) and older subjects (P<0.01). This may be due to the changes of menstrual activity around the age of 50, as the serum CA125 levels were higher in menstruating women and lower after menopause (Table I) .
According to these results, we determined the cut-off values as 20 U ml ' for males and 38 U ml ' for females. (Figure 4) . The existence of a pleural effusion did not affect the survival rate ( Figure 5; Days from the test Figure 3 Survival curves of patients with lung cancer depended on their serum CA125 level. a, all cases examined (CA125 + vs CA125-, P < 0.01). b, patients in stages 3 and 4 (CA125 + vs CA125-, P < 0.05). Figure 6 Survival curves of patients with stage 3 and 4 lung cancer based on its histological diagnosis (squamous cell lung cancer vs small cell lung cancer, P<0.05).
Discussion
We evaluated the serum CA125 levels of patients with lung cancer using a one-step immunoradiometric assay. Although previous reports have revealed close association between ovarian tumours and serum CA125 levels, there have been few papers which show the significance of CA125 in lung cancer. In this study, by setting different cut-off values for males and females, we found a high positive rate in advanced lung cancer. Furthermore, increased serum CA125 levels were observed in patients with a poor prognosis.
It is notable that 38% of patients with lung cancer had elevated serum CA125 levels, and that if one looks at stage 3 and 4 patients, the marker was present in 49% of those with squamous cell carcinoma (42% of those without effusions), 63% of those with adenocarcinoma (46% of those without effusions) and 69% of those with small call carcinoma (67% of those without effusions). CA125 is an antigen of ovarian adenocarcinoma cells, and recently it has been shown to exist on the ectodermal cells of the peritoneum and pleura (Kabawat et al., 1983b) . This may explain why most patients with pleural effusions or ascites had increased serum CA125 levels, but the marker was still present in relatively high percent of patients without effusions (42% of those with squamous cell carcinoma, 46% of those with adenocarcinoma and 67% of those with small cell carcinoma). Immunohistological examination demonstrated CA125 antigen in the lung adenocarcinoma but failed to demonstrate in the other types of lung cancer (Mutsuoka et al., 1987) . Although the site of production of CA125 in advanced stages is not clarified, we consider that those patients who were CA125 + without pleural effusions may have had microscopic invasion of the pleura and the serum level of this marker correlate to the stage of the disease. The cell type variations may be the area for a further study.
We found that an increased serum CA125 level indicated a bad prognostic factor for lung cancer. As CA125 + patients were more often stage 4 and more often had small cell cancer, the survival curves were compared between stages 3 and 4, among histological types, and between patients with and without pleural effusion. Although there were some differences between stages 3 and 4 and between squamous cell and small cell cancer, the CA125 levels (positive or not) was best correlated with survival time.
